In the ongoing Phase 3 GLOW2 study in DR, what are the potential implications and upsides for tarcocimab? DRSS: diabetic retinopathy severity score; GLOW 1 study NCT05066230; GLOW2 study NCT06270836 Primary Endpoint Initiating doses • Topline data expected Q1 2026. Key implications of GLOW2: • 1 st Phase 3 readout using the commercial formulation for tarcocimab , providing important safety data • 2 nd pivotal superiority study with 100% of patients on every 6-month (twice a year) dosing versus sham – evaluating ≥2-step improvement in DRSS (primary endpoint) and risk reduction in developing pre-specified sight-threatening complications (key secondary endpoint) • Features a similar study design as the successful GLOW1 study , with the benefit of an additional 3rd initiating dose • If successful, tarcocimab will have a BLA-ready profile for a filing in Diabetic Retinopathy (based on GLOW1 and GLOW2 studies) and in Retinal Vein Occlusion (based on BEACON study) Additional 3 rd initiating dose Superiority study 6-month dosing in all patients Topline data: Q1 2026 GLOW2 study design DR GLOW2 35 Quadrant of core unmet need